US Biosimilars Market Sales Revenue Clinical Trials Pipeline Report

Pharmaceutical companies benefited from the revolution in biotechnology that hit US market in 1980’s. Some of the blockbuster biologics have been introduced in market helping pharmaceutical companies to occupy major market shares. Their presence could be felt in every disease segment as they were improved with time. Over the years, biologics lost patent giving way to biosimilars. US is late entrant and its market is largely untouched by biosimilars resulting in lots of commercialization opportunities. Now, US has become center of attraction for generating significant revenues by introducing biosimilars in different disease categories. Future prospects of US biosimilars markets have yet to be deciphered as this market is at nascent stages offering unique opportunities and challenges.

Download Report:

https://www.kuickresearch.com/report-US-Biosimilars-Market-Opportunity-&-Clinical-Pipeline-Analysis.php

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

"US Biosimilars Market Opportunity & Clinical Pipeline Analysis" Table of Contents

1. US Biosimilars Market Introduction

2. US Biosimilars Regulatory Scenario

3. Unique Features of US Biosimilars Market

4. Impact of Biosimilars in US Market

5. New Biosimilar Categories with High Commercialization Potential
5.1 High Cost-Effectiveness
5.2 Competition
5.3 Nature of Indication
5.4 Nature of Biosimilars
5.5 Cost-Effective Production
5.6 Readily Availability of Biosimilars

6. Impact of Reimbursement Policies on US Biosimilars Market

7. Biobetters: Middle Ground between Biosimilars & Biologics

8. US Biosimilars Market Overview
8.1 Current Market Scenario
8.2 US Biosimilar Clincal Pipeline Overview

9. Zarxio: First Approved Biosimilar in US

10. US Biosimilars Market Dynamics
10.1 Research & Development
10.2 Increasing Demand for Biosimilars
10.3 Increasing Numbers Off-Patent Biologics
10.4 Lesser Competition
10.5 Strong Clinical Pipeline
10.6 Large Number of Indications to be Introduced

11. US Biosimilars Commercialization Challenges

12. US Biosimilars Future Prospects

13. US Biosimilars Market Guidelines
13.1 Scientific Considerations in Demonstration Biosimilarity to a Reference Product
13.2 Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein
Product to a Reference Product
13.3 Nonproprietary Naming of Biological Products
13.4 Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a
Reference Product

14. US Biosimilar Clinical Pipeline By Company, Indication & Phase
14.1 Research
14.2 Preclinical
14.3 Phase-I
14.4 Phase-I/II
14.5 Phase-II
14.6 Phase-III
14.7 Preregistration
14.8 Registered

15. Suspended & Discontued Biosimialrs in Clinical Pipeline
15.1 No Development Reported
15.2 Discountinued
15.3 Preregistration Submission Withdrawal

16. Competitive Landscape
16.1 Amgen
16.2 Apotex
16.3 Boehringer Ingelheim
16.4 Celltrion
16.5 Coherus BioSciences
16.6 Eli Lilly
16.7 EPIRUS Biopharmaceuticals
16.8 Finox Biotech
16.9 Harvest Moon Pharmaceuticals
16.10 Hospira
16.11 Intas Biopharmaceuticals
16.12 Juno Therepeutics (Opus Bio)
16.13 Merck
16.14 Momenta Pharmaceuticals
16.15 Mylan
16.16 Nora Therapeutics
16.17 Novartis
16.18 Oncobiologics
16.19 Pfenex
16.20 Pfizer
16.21 Sandoz
16.22 Wockhardt

Figure 1-1: Benefits of Biosimilar Introduction in US
Figure 1-2: Present Limitations of Biosimilars in US
Figure 1-3: FDA’s Requirements for Biosimilar Products
Figure 2-1: Criterias for Similarity Formulated by Food and Drug Administration (FDA)
Figure 4-1: Global Sales of Neupogen/Neulasta (USD Million), 2012-2014
Figure 4-2: Global Sales of Epogen (USD Million), 2012-2014
Figure 4-3: Global Sales of Neulasta (USD Million), 2012-2014
Figure 4-4: Shares of Amgen Products Exposed to Biosimilars Competition (USD Million), 2014
Figure 5-1: Factors Responsible for Significant Revenue Generation
Figure 7-1: Properties of Biobetters
Figure 7-2: Few Advantages of Biobetters
Figure 7-3: Disadvantages of Biobetters
Figure 8-1: US- Estimated Humira Sales (USD Million), 2012-2014
Figure 8-2: Global Remicade Sales (USD Million), 2012-2014
Figure 8-3: US- MabThera/Rituxan Quarterly Constant Exchange Rate Sales Growth (USD Million), Q3 2014-Q3 2015
Figure 8-4: US-Herceptin Quarterly Constant Exchange Rate Sales Growth (USD Million), Q3 2014- Q3 2015
Figure 8-5: Global Herceptin Quarterly Constant Exchange Rate Sales Growth (USD Million), Q3 2014-Q3 2015
Figure 8-6: Estimated Global Aranesp Sales (USD Million), 2012-2014
Figure 8-7: US- Estimated Aranesp Sales (USD Million), 2012-2017
Figure 8-8: Estimated Sales of Selected Biologics Exposed to Biosimilars Competition, 2014 (USD Million)
Figure 8-9: Estimated Shares of Selected Biologics Exposed to Biosimilars Competition (USD Million), 2014
Figure 8-10: Rank of US among Different Diabetes Prone Countries
Figure 8-11: US Biosimilar Pipeline by Phase (%),2016
Figure 8-12: US Biosimilar Pipeline by Phase (Number),2016
Figure 8-13: No Development Reported US Biosimilar All Pipeline by Phase (%),2016
Figure 8-14: No Development Reported US Biosimilar All Pipeline by Phase (Number),2016
Figure 8-15: Discontinued US Biosimilar All Pipeline by Phase (%),2016
Figure 8-16: Discontinued US Biosimilar All Pipeline by Phase (Numbers),2016
Figure 16-1: Amgen Clinical Pipeline
Figure 16-2: Coherus Bioscience Clinical Pipeline
Figure 16-3: EPIRUS Biopharmaceuticals- Clinical Pipeline
Figure 16-4: Merck Clinical Pipeline
Figure 16-5: Novartis Clinical Pipeline
Figure 16-6: Oncobiologics-Clinical Pipeline
Figure 16-7: Pfenex Clinical Piepline
Figure 16-8: Sandoz Clinical Pipeline

List of Tables

Table 2-1: Major Regulatory Differences Related to Biosimilars in US & EU
Table 2-2: Differences between Biosimilars Applications & Biologics License Applications
Table 4-1: Comparison of Neupogen vs. Zarxio Cost
Table 4-2: Competition to Neupogen
Table 4-3: Amgen’s Biosimilar Competitors in US
Table 4-4: Categories with Potential to Generate Significant Revenues in US Market
Table 5-1: Biosimilars under Food and Drug Administration (FDA) Review
Table 6-1: Categories of Medicare Plan
Table 6-2: Estimated Reimbursement of Zarxio according to Medicare B
Table 7-1: Few Examples of Biologics, Biosimilars and Biobetters
Table 8-1: Biosimilars with High Commercialization Potential in US, 2013-2024
Table 8-2: Companies Involved in Marketing of Rituximab
Table 8-3: Categories with High Potential for Biosimilar Revenue Generation
Table 16-1: Celltrion Clinical Pipeline

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.